NCT03618134 - Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Human Papillomavirus PositiveOropharyngeal Squamous Cell Carcinomap16 Positive Neoplastic Cells PresentPathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions

BIOLOGICAL

Durvalumab

Given IV

PROCEDURE

Modified Radical Neck Dissection

Undergo modified radical neck dissection

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

PROCEDURE

Transoral Robotic Surgery

Undergo TORS

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles